Gland Pharma任命Shyamakant Giri为首席执行官,于2025年1月15日生效,以加强领导和推动增长。 Gland Pharma appoints Shyamakant Giri as CEO, effective Jan 15, 2025, to enhance leadership and drive growth.

Gland Pharma已任命Shyamakant Giri为新的首席执行官,自2025年1月15日起生效。 Gland Pharma has appointed Shyamakant Giri as its new CEO, effective January 15, 2025. Giri在医药和保健部门积累了25年的经验,在Amneal制药公司、Abbott和Rivaara实验室担任领导职务。 Giri brings over 25 years of experience in the pharmaceutical and healthcare sectors, having held leadership roles at Amneal Pharmaceuticals, Abbott, and Rivaara Labs. 他的任命是Gland Pharma加强领导和推动增长战略的一部分。 His appointment is part of Gland Pharma’s strategy to enhance leadership and drive growth. 现任首席执行官Srinivas Sadu在过渡期间将继续担任执行主席。 Current CEO Srinivas Sadu will remain as executive chairman during this transition.